Parkinson's sleep study halted early – what we know
NCT ID NCT03968744
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether the drug safinamide (Xadago) could improve sleep quality in people with Parkinson's disease. Eleven participants took safinamide for 12 weeks while their sleep was measured. The trial was terminated early, so the results are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- safinamide (Xadago)
- What this could lead to
- If it works, this could point toward a treatment for sleep problems in Parkinson's disease.
- What could go wrong
- The trial was terminated early and had only 11 participants, so results are very limited. It is unclear if safinamide truly helps sleep.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PARKINSON'S DISEASE (AT LATER STAGE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Neurocenter of Southern Switzerland - Ente Ospedaliero Cantonale (EOC)
Lugano, 6900, Switzerland